Articles tagged with Myeloma
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A new study published in JNCCN finds that a cost-effective education program targeting survivors and their doctors can increase screening rates for skin cancer. The study showed that practical solutions can close the gap between elevated risks and low screening rates, especially after transitioning out of specialty care.
Researchers found that a new treatment regimen can slow cancer progression in patients with functional high-risk (FHR) multiple myeloma. The study defines FHR multiple myeloma as progressing within 36 months of starting treatment, indicating a survival prognosis of less than 2 years after progression.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
In a landmark international trial, teclistamab outperformed standard treatments in extending survival and remission for patients with relapsed multiple myeloma. Nearly 70% of patients remained disease-free after 18 months, and nearly two-thirds achieved complete remission.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
A new study found that bilingual consent forms significantly improve cancer treatment understanding among people with limited English, with understanding rising from 35% to 60%. The study, published in Supportive Care in Cancer, examined the impact of different translation approaches on cancer treatment understanding among Bengali- and...
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
A new study published in CANCER found that men are more likely to have advanced disease and high myeloma load at diagnosis compared to women. Men were also less likely to have low bone mineral density and had different chromosomal abnormalities, which may contribute to the sex disparity in multiple myeloma risk.
CORAL accurately predicts genetic subtypes and patient outcomes in multiple myeloma without costly genomic tests. The technology could be applied to other cancers, opening the door to personalized, faster and widely accessible cancer care.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A new study reveals that DNA damage in multiple myeloma initiates 2-4 decades before diagnosis, with key genomic events including IGH translocation and chr 1q gain. These findings may lead to new precision medicine treatment strategies for patients.
A new silicone patch with star-shaped microneedles, called the ExoPatch, distinguishes melanoma from healthy skin in mice, capturing cancer biomarkers from exosomes. The test shows promise for early detection of the most aggressive form of skin cancer without a biopsy or blood draw.
The Josep Carreras Leukaemia Research Institute is launching a joint research programme on childhood leukaemia, aiming to develop common strategies and improve treatments for the disease. Paediatric leukaemia remains a significant challenge due to its low incidence and high mortality rate.
A high-fiber plant-based diet improved health markers that could delay the progression of precancerous conditions and multiple myeloma. The study showed significant improvements in dietary quality, weight loss, metabolic markers, inflammation, and gut microbiome diversity.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A case of therapy-related B-lymphoblastic leukemia (B-ALL) following multiple myeloma treatment is reported, characterized by unusual surface kappa light chain expression. The diagnosis was made based on immunophenotypic analysis and next-generation gene sequencing, which revealed pathogenic mutations in KDM6A and KRAS.
Researchers found that NSD2 helps maintain MM cell identity by reorganizing DNA and influencing gene activity. This discovery could shape future treatment approaches for patients with t(4;14) myeloma.
A team of international researchers found that tumor cells become drastically diverse when exiting the bone marrow, affecting immune cells in the cancer lesions. This discovery could contribute to more precise diagnostics and therapy for multiple myeloma, a incurable bone marrow cancer.
Researchers found that pomalidomide enhances key immune cells, such as T cells and natural killer cells, which helps the body recognize and destroy cancer cells. This leads to improved immune profiles in patients with myeloma, resulting in longer progression-free survival periods.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
Researchers are working to develop a curative treatment for multiple myeloma by combining treatments, overcoming resistance, and tailoring therapy to individual patients. The study found promising results using bispecific antibodies in combination with other treatments.
Researchers unveil retrotransposon-derived DNA zip codes that enable myeloma cell internalization, shedding light on cancer evolution and treatment response. The findings highlight the potential of zip-code technology in improving patient outcomes and advancing human health.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Researchers found decreased BMAd density and altered distribution profile in MGUS patients who developed MM, indicating early changes in bone marrow adipose tissue. These findings suggest the potential for timely interventions and personalized treatment strategies.
Researchers found that obesity is associated with a 73% higher odds of having monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that often precedes multiple myeloma. Lifestyle factors such as physical activity and smoking habits also play a role in the development of MGUS.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
Researchers have discovered that NSD2 triggers aggressive myeloma by activating PKCα, leading to excessive lactate production. This study presents potential targets for improved treatment of high-risk myeloma subtypes.
A new oral agent called mezigdomide has shown impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies. The treatment produced a response rate of over 40% and a median duration of response of almost 8 months.
Researchers found that ketogenic diets delay tumour growth but accelerate cachexia, a wasting syndrome that worsens disease prognosis. Dexamethasone may help optimise benefits by delaying cachexia.
A breakthrough treatment targeting bone marrow cancer cells destroyed 90% of multiple myeloma cells in laboratory tests and 60% in human tissue samples. Researchers developed lipid-based nanoparticles containing RNA molecules that silence the CKAP5 gene, inhibiting cancer cell division.
A Phase I and Phase II clinical trial of the immunotherapy REGN5459 resulted in a 90.5 percent overall response rate among patients with relapsed multiple myeloma. The treatment is reasonably tolerated, with common side effects including cytokine release syndrome.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Two novel genetically defined mouse models replicate two subtypes of human multiple myeloma, revealing the interaction of genetic aberrations as a key factor in development. The models will aid in identifying specific therapeutic strategies for individualized treatment.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
Researchers uncover critical shape-change in cereblon protein that CELMoD drugs must cause to work effectively. The finding enables the development of more effective cancer-fighting treatments.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers at the University of South Australia are using new technologies to speed up blood cancer diagnosis and treatment. The project aims to identify genetic variants that cause cancer, enabling clinicians to provide targeted treatments and improve patient management.
A study of over 500 patients with multiple myeloma reveals a high prevalence of genetic alterations in oncogenic pathways, leading to treatment resistance. The research found a specific link between RASopathies and mutations in these pathways, offering new insights into the development of resistance mechanisms.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Patients with mild to moderate kidney disease and kidney transplant recipients had a higher risk of cancer. They also faced a higher risk of dying from cancer, particularly from cancers such as bladder, kidney, and multiple myeloma, compared to those with normal kidney function.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Researchers uncover how histone demethylase KDM5A promotes myeloma cell proliferation by regulating histone methylation. A novel KDM5 inhibitor inhibits cancer cell growth and is expected to develop into a new therapeutic strategy for multiple myeloma and other cancers.
A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times. Nearly three-quarters of the patients had at least a partial response to the therapy, with about a third achieving complete remission.
In a major advance, CAR T-cell therapy ide-cel has generated deep, sustained remissions in patients who had relapsed from several previous therapies. Almost 75% of participants responded to the therapy, and one-third had a complete response or disappearance of all signs of their cancer.
The new guidelines recommend broadening eligibility criteria and requiring diversity study plans to increase African American participation. Gathering clinical trial data post-approval can also identify differences in safety and efficacy among racial subpopulations.
Researchers from King's College London found that whole-body magnetic resonance imaging (WBMRI) detects more myeloma cases than traditional PET/CT tests. The study showed that WBMRI allowed for critical treatment to be initiated earlier in 24% of cases, resulting in improved patient outcomes.